Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

NCT00052884 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

NETWORK

Sponsor class

Stopped Slow accrual and changes in clinical practice

Conditions

Drug/Agent Toxicity by Tissue/Organ
Multiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL: filgrastim
DRUG: amifostine trihydrate
DRUG: melphalan
PROCEDURE: bone marrow ablation with stem cell support
PROCEDURE: peripheral blood stem cell transplantation

Sponsor

Eastern Cooperative Oncology Group

Collaborators

[object Object]